Therapeutic Proteins and Oral Vaccines Market
完整報告名稱與涵蓋範圍
Therapeutic Proteins and Oral Vaccines Market Size, Share & Trends Analysis Report By Drug Class, By Distribution Channel, By Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, Other Applications), By Region, And By Segment Forecasts, 2024-2031
報告摘要
Across the 2024 to 2031 projection horizon, the worldwide Therapeutic Proteins and Oral Vaccines Market is poised to register a CAGR of 8.1%.
At its core, Therapeutic Proteins and Oral Vaccines pertains to key industry insights & findings from the report:
The rise in severe diseases such as cancer, diabetes, and autoimmune disorders has increased the demand for therapeutic proteins. Stakeholders across the healthcare landscape are escalatingly turning to these solutions to meet contemporary demands.
Market momentum is supported by escalating requirement advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, supported by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Therapeutic Proteins and Oral Vaccines Market Snapshot
Chapter 4. Global Therapeutic Proteins and Oral Vaccines Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Drug Class, Estimates & Trend Analysis
5.1. By Drug Class, & Market Share, 2019 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Drug Class:
5.2.1. Therapeutic Proteins
5.2.1.1. Growth Factors
5.2.1.2. Fusion Proteins
5.2.1.3. Monoclonal Antibodies
5.2.1.4. Hormones
5.2.1.5. Coagulation Factors
5.2.1.6. Other Therapeutic Proteins
5.2.2. Oral Vaccines
5.2.2.1. Live Attenuated Vaccine
5.2.2.2. Inactivated Vaccine
5.2.2.3. Recombinant Vaccine
5.2.2.4. Other Oral Vaccines
Chapter 6. Market Segmentation 1: By Distribution Channels Estimates & Trend Analysis
6.1. By Distribution Channels & Market Share, 2019 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Distribution Channels:
6.2.1. Hospital Pharmacies
6.2.2. Retail Pharmacies
6.2.3. Online Pharmacies
Chapter 7. Market Segmentation 1: By Applications Estimates & Trend Analysis
7.1. By Applications & Market Share, 2019 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Applications:
7.2.1. Oncology
7.2.2. Hematology
7.2.3. Immunology
7.2.4. Endocrinology
7.2.5. Infectious Disease
7.2.6. Cardiovascular Disease
7.2.7. Other Applications
Chapter 8. Therapeutic Proteins and Oral Vaccines Market Segmentation 3: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) estimates and forecasts By Drug Class, 2024-2031
8.1.2. North America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) estimates and forecasts By Distribution Channels, 2024-2031
8.1.3. North America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) estimates and forecasts By Applications, 2024-2031
8.1.4. North America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Drug Class, 2024-2031
8.2.2. Europe Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Distribution Channels, 2024-2031
8.2.3. Europe Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Applications, 2024-2031
8.2.4. Europe Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Drug Class, 2024-2031
8.3.2. Asia Pacific Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Distribution Channels, 2024-2031
8.3.3. Asia Pacific Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Applications, 2024-2031
8.3.4. Asia Pacific Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) by country, 2024-2031
8.4. Latin America
8.4.1. Latin America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Drug Class, (US$ Million) 2024-2031
8.4.2. Latin America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Distribution Channels, (US$ Million) 2024-2031
8.4.3. Latin America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Applications, (US$ Million) 2024-2031
8.4.4. Latin America Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) by country, (US$ Million) 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Drug Class, (US$ Million) 2024-2031
8.5.2. Middle East & Africa Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Distribution Channels, (US$ Million) 2024-2031
8.5.3. Middle East & Africa Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) By Applications, (US$ Million) 2024-2031
8.5.4. Middle East & Africa Therapeutic Proteins and Oral Vaccines Market revenue (US$ Million) by country, (US$ Million) 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Abbott Laboratories
9.2.2. Amgen, Inc.
9.2.3. Biogen, Inc.
9.2.4. Eily, Lilly, and Company
9.2.5. F. Hoffmann-La Roche
9.2.6. Johnson and Johnson
9.2.7. Merck & Co.
9.2.8. Novo Nordisk
9.2.9. Pfizer, Inc.
9.2.10. Sanofi S.A.
9.2.11. Serum Institute of India Pvt. Ltd.
9.2.12. Emergent Biosolutions Inc.
9.2.13. TransAlgae
9.2.14. MigVax Ltd
9.2.15. Lumen Bioscience, Inc.
9.2.16. Neurelis, Inc.
9.2.17. Other Prominent Player
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們